Quick Answer
BIOXYTRAN, INC reported R&D Expense of $112.3 thousand for fiscal year 2024.
BIOXYTRAN, INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $112.3K | -90.2% |
| 2023 | $1.15M | +17.5% |
| 2022 | $977.8K | -51.4% |
| 2021 | $2.01M | +269.8% |
| 2020 | $544.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $102.5K | — | -70.7% |
| March 31, 2025 | $349.5K | +1194.4% | +585.3% |
| September 30, 2024 | $51.0K | -83.9% | +88.9% |
| March 31, 2024 | $27.0K | -80.6% | -91.5% |
| September 30, 2023 | $316.1K | -33.6% | +111.3% |
| June 30, 2023 | $149.6K | +246.9% | +7.7% |
| March 31, 2023 | $139.0K | -42.1% | -70.8% |
| September 30, 2022 | $475.9K | +161.5% | +1003.1% |
- BIOXYTRAN, INC showed a decrease of -90.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2024 period, BIOXYTRAN, INC’s r&d expense has declined by 79.4% (from $544.5 thousand to $112.3 thousand).
- The most recent figure is from BIOXYTRAN, INC’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: